Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Achieve Life Sciences typically reports earnings before market open, meaning Day 0 reflects anticipation and Day +1 captures the market's first full reaction to results.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-11-10 | -$0.38 (-5.60%) | $0.67 (9.88%) | +$0.05 (+0.78%) | $0.26 (4.14%) |
| 2026-08-11 | +$0.10 (+1.50%) | $0.42 (6.28%) | -$0.08 (-1.18%) | $0.26 (3.84%) |
| 2026-05-12 | +$0.40 (+7.16%) | $0.80 (14.31%) | -$0.03 (-0.50%) | $0.47 (7.78%) |
| 2026-03-24 | -$1.15 (-28.40%) | $0.89 (21.98%) | -$0.08 (-2.76%) | $0.27 (9.48%) |
| 2025-11-06 | -$0.19 (-3.85%) | $0.38 (7.81%) | -$0.15 (-3.16%) | $0.40 (8.44%) |
| 2025-08-07 | +$0.00 (+0.00%) | $0.19 (7.39%) | -$0.14 (-5.30%) | $0.14 (5.19%) |
| 2025-05-13 | +$0.17 (+6.85%) | $0.18 (7.43%) | -$0.17 (-6.42%) | $0.23 (8.87%) |
| 2025-03-11 | -$0.14 (-4.58%) | $0.16 (5.21%) | -$0.27 (-9.25%) | $0.31 (10.45%) |
| Avg Abs Move | 7.24% | 10.04% | 3.67% | 7.27% |
Achieve Life Sciences exhibits high post-earnings volatility, with an average absolute Day 0 move of 7.24% and Day +1 follow-through averaging 3.67%. The stock's reaction has been directionally mixed, with no clear pattern of beats or misses correlating to positive or negative moves.
The most recent earnings (November 10, 2026) saw the stock decline 5.60% on Day 0 despite beating estimates by $0.09, with a total intraday range of 9.88%—suggesting significant investor uncertainty even in the face of better-than-expected results. The Day +1 move was a modest gain of 0.78%, indicating limited follow-through conviction.
The largest single-day move occurred on March 24, 2026, when the stock plunged 28.40% on Day 0 with a 21.98% intraday range—one of the most volatile sessions in the company's recent history. This coincided with the quarter that ultimately beat estimates, suggesting the market was reacting to guidance, cash burn concerns, or regulatory commentary rather than the headline EPS figure.
Historically, Day 0 moves have ranged from flat (August 2025) to double-digit swings in both directions, with the average Day 0 range of 10.04% highlighting the stock's sensitivity to earnings events. Day +1 moves are generally more muted but still meaningful, averaging 7.27% in total range, indicating continued digestion of results and management commentary into the following session.
Achieve Life Sciences commands unanimous bullish sentiment from the analyst community, with all 10 analysts rating the stock a Strong Buy and zero Hold or Sell ratings. This represents an unchanged consensus over the past month, reflecting sustained confidence despite the regulatory delay.
The average price target stands at $13.45, implying 127% upside from the current price of $5.92. Analyst targets range from a low of $10.00 to a high of $21.00, with the wide spread reflecting differing assumptions around commercialization timelines, market penetration, and the value of the vaping cessation opportunity. The high-end target of $21.00 suggests some analysts see cytisinicline as a potential blockbuster if both smoking and vaping indications are approved.
The 5.00 average recommendation (on a scale where 5 = Strong Buy) represents the most bullish possible consensus rating. This level of conviction is notable for a pre-revenue biotech company that recently received a Complete Response Letter, underscoring analyst belief that the manufacturing issues are resolvable and that the clinical data supporting cytisinicline remains compelling.
Sentiment has remained unchanged over the past month, with the 10 Strong Buy ratings holding steady. This stability suggests analysts view the Q4 2026 NDA resubmission timeline as credible and are looking past the near-term regulatory noise to the potential commercial opportunity. The lack of any Hold or Sell ratings indicates no major concerns about the company's ability to navigate the resubmission process or secure eventual approval.
Achieve Life Sciences enters earnings in a deteriorating technical position, with the Barchart Technical Opinion shifting from a Buy signal at 24% a month ago to a Sell signal at just 8% currently. The signal also weakened from 8% Buy last week, indicating accelerating negative momentum in the very near term.
Timeframe Analysis:
Trend Characteristics: The trend is characterized by Minimum strength and Average direction, suggesting weak momentum and lack of conviction in either direction heading into the earnings event. This tepid technical environment reflects investor uncertainty around both the quarterly results and the broader regulatory timeline.
The stock is trading below its 5-day ($6.14), 10-day ($6.34), 20-day ($6.55), 50-day ($7.02), and 100-day ($7.00) moving averages, indicating sustained selling pressure across all short- and intermediate-term timeframes. The only positive technical is the stock's position above the 200-day moving average ($5.74), which provides long-term support but offers little comfort given the breakdown below all shorter-term averages.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $6.14 | 50-Day MA | $7.02 |
| 10-Day MA | $6.34 | 100-Day MA | $7.00 |
| 20-Day MA | $6.55 | 200-Day MA | $5.74 |
The technical setup heading into earnings is cautionary, with the stock in a clear downtrend across multiple timeframes despite trading above long-term support. The shift from a 24% Buy signal a month ago to an 8% Sell signal today suggests deteriorating sentiment, potentially driven by concerns about the NDA resubmission timeline or broader biotech sector weakness. The stock's position below all moving averages from 5 to 100 days signals that buyers have stepped away, and the weak momentum (Minimum strength, Average direction) suggests limited conviction in either direction. For a stock with 127% upside to analyst targets and a critical regulatory catalyst approaching, the technical weakness may present either a buying opportunity for long-term investors or a warning sign that the market is pricing in execution risk around the Q4 resubmission.